Canature Health Technology Co., Ltd. (SHE:300272)
China · Delayed Price · Currency is CNY 7.49
-0.24 (-3.10%)
Apr 30, 2026, 3:08 PM CST
SHE:300272 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,841 | 1,679 | 1,659 | 1,645 | 1,489 |
Other Revenue | - | 9.16 | 12.51 | 15.67 | 22.71 |
| 1,841 | 1,689 | 1,672 | 1,661 | 1,511 | |
Revenue Growth (YoY) | 9.03% | 1.00% | 0.67% | 9.87% | 27.97% |
Cost of Revenue | 1,123 | 1,041 | 1,056 | 1,112 | 1,010 |
Gross Profit | 718.37 | 647.28 | 615.87 | 548.75 | 501.96 |
Selling, General & Admin | 427.26 | 413.52 | 384.05 | 346.17 | 304.05 |
Research & Development | 83.14 | 67.57 | 65 | 63.94 | 51.49 |
Other Operating Expenses | -1.14 | 5.58 | 5.83 | 9.04 | 3.26 |
Operating Expenses | 509.26 | 486.61 | 457.05 | 419.71 | 361.57 |
Operating Income | 209.11 | 160.67 | 158.82 | 129.04 | 140.39 |
Interest Expense | - | -34.48 | -28.44 | -16.85 | -16.28 |
Interest & Investment Income | - | 22.55 | 14.87 | 5.54 | 32.26 |
Currency Exchange Gain (Loss) | - | 19.75 | 9.58 | 10.12 | 0.84 |
Other Non Operating Income (Expenses) | -40.94 | -5.22 | -4.41 | -9.23 | -5.48 |
EBT Excluding Unusual Items | 168.17 | 163.27 | 150.41 | 118.63 | 151.72 |
Impairment of Goodwill | - | - | - | -15.32 | -5.82 |
Gain (Loss) on Sale of Investments | -55.88 | -33.5 | 4.66 | 2.6 | -2.43 |
Gain (Loss) on Sale of Assets | -0.14 | -0.17 | 2.33 | 1.4 | -0.7 |
Asset Writedown | -1.96 | - | - | - | -0.19 |
Legal Settlements | - | -3.73 | -0.24 | - | -3.71 |
Other Unusual Items | - | 9.13 | 1.64 | 6.96 | 6.61 |
Pretax Income | 110.19 | 135 | 158.81 | 114.27 | 145.49 |
Income Tax Expense | 30.12 | 21.56 | 5.33 | 15.24 | 28.39 |
Earnings From Continuing Operations | 80.07 | 113.45 | 153.48 | 99.03 | 117.1 |
Minority Interest in Earnings | -24.06 | -29.87 | -21.03 | -6.47 | -12.24 |
Net Income | 56.01 | 83.58 | 132.45 | 92.56 | 104.86 |
Net Income to Common | 56.01 | 83.58 | 132.45 | 92.56 | 104.86 |
Net Income Growth | -32.98% | -36.90% | 43.09% | -11.73% | 296.93% |
Shares Outstanding (Basic) | 580 | 566 | 562 | 566 | 583 |
Shares Outstanding (Diluted) | 580 | 579 | 573 | 566 | 583 |
Shares Change (YoY) | 0.28% | 1.03% | 1.19% | -2.82% | 10.26% |
EPS (Basic) | 0.10 | 0.15 | 0.24 | 0.16 | 0.18 |
EPS (Diluted) | 0.10 | 0.14 | 0.23 | 0.16 | 0.18 |
EPS Growth | -33.17% | -37.54% | 41.41% | -9.17% | 260.00% |
Free Cash Flow | 154.89 | 189.98 | 294.59 | 60.85 | 115.48 |
Free Cash Flow Per Share | 0.27 | 0.33 | 0.51 | 0.11 | 0.20 |
Dividend Per Share | - | 0.160 | 0.100 | 0.100 | 0.100 |
Dividend Growth | - | 60.00% | - | - | 100.00% |
Gross Margin | 39.02% | 38.34% | 36.84% | 33.04% | 33.21% |
Operating Margin | 11.36% | 9.52% | 9.50% | 7.77% | 9.29% |
Profit Margin | 3.04% | 4.95% | 7.92% | 5.57% | 6.94% |
Free Cash Flow Margin | 8.41% | 11.25% | 17.62% | 3.66% | 7.64% |
EBITDA | 273.22 | 208.02 | 208.85 | 181.79 | 183.42 |
EBITDA Margin | 14.84% | 12.32% | 12.49% | 10.95% | 12.13% |
D&A For EBITDA | 64.11 | 47.35 | 50.03 | 52.76 | 43.02 |
EBIT | 209.11 | 160.67 | 158.82 | 129.04 | 140.39 |
EBIT Margin | 11.36% | 9.52% | 9.50% | 7.77% | 9.29% |
Effective Tax Rate | 27.33% | 15.97% | 3.36% | 13.34% | 19.51% |
Revenue as Reported | - | 1,689 | 1,672 | 1,661 | 1,511 |
Advertising Expenses | - | 14.35 | 10.59 | 0.13 | 1.4 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.